An ideal diagnostic test should be quick, reliable and noninvasive. Fecal calprotectin is considered a marker of intestinal inflammation and has proven to be an effective test for IBD, but is fecal calprotectin a useful diagnostic tool when assessing patients with cirrhosis?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Zwadlo, G., Schlegel, R. & Sorg, C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J. Immunol. 137, 512–518 (1986).
Gundling, F. et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathyand spontaneous bacterial peritonitis in cirrhosis. Liver Int. 31, 1406–1411 (2011).
Striz, I. & Trebichavsky, I. Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol. Res. 53, 245–253 (2004).
Garcia-Sanchez, V. et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J. Crohns Colitis 4, 144–152 (2010).
Homann, C. et al. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology 21, 979–985 (1995).
Gupta, A. et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J. Hepatol. 53, 849–855 (2010).
Mullen, K. & Prakash, R. Rifaximin for the treatment of hepatic encephalopathy. Expert Rev. Gastroenterol. Hepatol. 4, 665–677 (2010).
Bajaj, J. S. et al. Review article: the design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment. Pharmacol. Ther. 33, 739–747 (2011).
Prakash, R. K. & Mullen, K. D. Is poor quality of life always present with minimal hepatic encephalopathy? Liver Int. 31, 908–910 (2011).
Runyon, B. A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 49, 2087–2107 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K. D. Mullen declares that he has worked as a consultant and been a member of a speakers bureau for Salix Pharmaceuticals. R. K. Prakash declares no competing interests.
Rights and permissions
About this article
Cite this article
Prakash, R., Mullen, K. Intestinal inflammation—key to complications in cirrhosis?. Nat Rev Gastroenterol Hepatol 8, 665–667 (2011). https://doi.org/10.1038/nrgastro.2011.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.209